| P2093 | author name string | Anastasios Athanasopoulos | |
| | Petros Perimenis | |
| | Konstantinos Giannitsas | |
| | Angelis Konstantinopoulos | |
| P2860 | cites work | How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study | Q28202479 |
| | Pharmacology of the lower urinary tract | Q34192787 |
| | Tolterodine: an overview | Q34473206 |
| | Oxybutynin and the overactive bladder | Q34473215 |
| | Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). | Q34473221 |
| | Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia | Q34473227 |
| | The emerging role of solifenacin in the treatment of overactive bladder | Q34551577 |
| | Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review | Q34950386 |
| | Antimuscarinics for treatment of overactive bladder | Q35615145 |
| | Clinical and socioeconomic relevance of overactive bladder. | Q35687979 |
| | Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder | Q35925590 |
| | Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence | Q35938505 |
| | The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis | Q36122988 |
| | Prevalence of the overactive bladder syndrome by applying the International Continence Society definition | Q39720841 |
| | Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. | Q40450175 |
| | Cost-per-QALY league tables: their role in pharmacoeconomic analysis. | Q41033436 |
| | Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model | Q42686882 |
| | Intravesical oxybutynin: a local anesthetic effect on bladder C afferents | Q44398144 |
| | Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study | Q44456798 |
| | Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder | Q44862823 |
| | Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity | Q44973533 |
| | Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder | Q45100348 |
| | Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity | Q45153417 |
| | Health-related consequences of overactive bladder: an economic perspective | Q45235161 |
| | Costs of urinary incontinence and overactive bladder in the United States: a comparative study. | Q45969424 |
| | Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. | Q46557454 |
| | A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial | Q46577111 |
| | Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis | Q46591360 |
| | Impact of urinary incontinence and overactive bladder on quality of life | Q46717071 |
| | Estimated economic costs of overactive bladder in the United States | Q46914426 |
| | Employees with overactive bladder: work loss burden. | Q50761314 |
| | Willingness to pay for reduced incontinence symptoms. | Q50927042 |
| | Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. | Q51966491 |
| | The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 |
| | A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. | Q53342637 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 539-544 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome | |
| P478 | volume | 7 | |